Omnicell (NASDAQ:OMCL) Stock Rating Lowered by StockNews.com

Omnicell (NASDAQ:OMCL - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Saturday.

Several other analysts have also commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. Benchmark reiterated a "buy" rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Finally, Wells Fargo & Company dropped their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $45.83.

Omnicell Stock Up 3.3 %

Omnicell stock traded up $0.81 during midday trading on Friday, hitting $25.44. 93,498 shares of the company's stock were exchanged, compared to its average volume of 546,842. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market cap of $1.19 billion, a PE ratio of 94.23, a P/E/G ratio of 7.53 and a beta of 0.78. The firm has a 50-day moving average of $32.76 and a two-hundred day moving average of $40.17.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company posted $0.03 earnings per share. As a group, analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Hedge funds have recently made changes to their positions in the company. Lazard Asset Management LLC lifted its holdings in Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after acquiring an additional 737,536 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after purchasing an additional 699,925 shares during the last quarter. Toronto Dominion Bank purchased a new position in shares of Omnicell during the 4th quarter worth $30,637,000. Dimensional Fund Advisors LP increased its position in shares of Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after acquiring an additional 377,883 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.